Ablynx

Nanobodies®
creating better medicines

2016 full year results

Webcast presentation – 23 February 2017

Ablynx 2016 full year results presentation

Participants on the call

Dr Edwin Moses

CEO

Wim Ottevaere

CFO

Dr Robert K. Zeldin

CMO

Forward looking statements

Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation.

Ablynx 2016 full year results presentation

Agenda

- Welcome and introduction
- Financial highlights
- Operational performance
- Outlook
- Q&A
- Conclusion



Financial highlights

Financial results and shareholder base

Ablynx

Financial summary

Full year results 2016

€ million	FY 2016	FY 2015	Change
Total revenue and grant income	**85.2**	**77.5**	**10%**
R&D income	84.8	76.8	10%
Grants	0.4	0.7	(43%)
Operating expenses	**(113.8)**	**(94.5)**	**20%**
R&D	(100.3)	(83.1)	21%
G&A	(13.5)	(11.4)	18%
Operating result	**(28.6)**	**(17.0)**	**(68%)**
Net financial result	**27.5**	**(37.6)**	**>100%**
Net result	**(1.1)**	**(54.5)**	**98%**
Net cash flow	**(72.2) (1)**	**(67.2) (3)**	**(7%)**
Cash* at 31 December	**235.4 (2)**	**236.2 (2)**	**-**

(1) excluding €71.4 million net proceeds from the private placement of new shares, announced on 1 June 2016

(2) including €1.6 million in restricted cash

(3) excluding €97.2 million net proceeds from the convertible bond, announced on 20 May 2015

* defined as liquidity position in the cash flow statement

Ablynx

Diversified shareholder base – January 2017

- Ordinary shares listed on Euronext Brussels (ABLX)
- Sponsored Level I ADRs on the US OTC market (ABYLY)
- 61.1M shares outstanding
- 2.5M outstanding warrants (in number of shares)

Breakdown of share capital



% of Institutional Shareholders by Geography (representing 87% of total S/O)



Product pipeline

Good progress in key pre-clinical and clinical development programmes

Ablynx

Broad product pipeline

>45 programmes, 8 Nanobodies® in clinical development

Product	Indication	Target	Pre-clinical	Phase I	Phase II	Phase III	Filing
caplacizumab	aTTP	vWF					★
vobarilizumab	RA	IL-6R					
	SLE	IL-6R					
ALX-0171	RSV	RSV					
Up to 17 programmes	Immuno-Oncology	Various					
ozoralizumab	RA	TNFα				Japan	
	RA	TNFα		Greater China			
ALX-0761/M1095	Psoriasis	IL-17A/IL-17F					
BI 836880	Oncology	VEGF/Ang2					
BI 655088	Chronic kidney disease	CX3CR1					
NA	Inflammation	CXCR2					
ALX-0141	Bone disorders	RANKL		Greater China			
>15 wholly-owned and partnered programmes	Various						

★ Filing in EU based on Phase II TITAN data

Caplacizumab – anti-vWF Nanobody

First-in-class potential for the treatment of aTTP

- Acquired thrombotic thrombocytopenic purpura (aTTP) is a very rare blood clotting disease with reported incidence up to 11 per million
- There is no drug treatment currently indicated for aTTP
- Standard-of-care (SOC): plasma exchange + immunosuppressants
- Even with the current SOC, mortality of up to 20% is observed and patients also suffer serious long-term morbidities and recurrence of disease

Caplacizumab

2016 achievements



- Publication of the Phase II data from TITAN in the New England Journal of Medicine (NEJM)
- Post-hoc analysis of data from the TITAN study reported:
  - caplacizumab dramatically reduced the frequency of major thromboembolic events and death compared to placebo (11% vs 43%)
- Start of 3-year follow-up study for patients completing the Phase III HERCULES study
- Recruited the 100th patient in the Phase III HERCULES study

Caplacizumab

Post-period highlights and catalysts in 2017-2018

- Submitted MAA to the EMA on 3 February 2017 ✓
- Start Phase I study in Japanese healthy volunteers – results expected in H2 2017
- Report topline results from Phase III HERCULES study – expected in H2 2017
- Submit BLA to the FDA – expected in H1 2018
- Continue preparations to lead commercialisation in Europe and North America
- Building Medical Affairs capabilities
  - recruited first Medical Science Liaison (MSL) in Germany ✓

- **Anticipated first launch in Europe in 2018**
- **Forecast peak sales of >€400M[1]**

[1]USA, Canada, EU and Japan

ALX-0171 – inhaled anti-RSV Nanobody

Potential breakthrough for the treatment of RSV infections

- Respiratory syncytial virus (RSV) – a viral infection of the lungs
- 3.4 million infants hospitalised with RSV annually worldwide[1]
- Globally RSV is estimated to cause 66,000-199,000 deaths each year[1]
- Long-term disease burden[2]
- ALX-0171 – a trivalent anti-RSV Nanobody delivered by inhalation

[1]Mazur *et al,* Lancet 2015; [2]Shi *et al*, J Med Econ, 2011

ALX-0171

2016 achievements

May *preparations for Phase IIb study*

Completed first-in-infant Phase I/IIa study

- recruited 53 infants, aged 1-24 months, who had been hospitalised as a result of a RSV infection
- reported excellent safety and encouraging efficacy data
  - no treatment-related serious adverse events
  - immediate and significant impact on viral replication and reduction in viral load, as compared to placebo

ALX-0171

Post-period highlights and catalysts in 2017-2018

- Global Phase IIb RESPIRE study in infants hospitalised for a RSV infection
  - first patient recruited in January 2017 ✓
  - continue recruitment of 180 infants between 28 days and <2 years of age
  - report topline results – expected H2 2018

- Initiate clinical development for Japan

- Initiate clinical development in stem cell transplantation patients with a RSV infection

Vobarilizumab – anti-IL-6R Nanobody

Novel potential best-in-class treatment for RA

- AbbVie paid $175M in 2013 as part of an option deal on vobarilizumab
- Ablynx has been responsible for running two Phase IIb studies in RA and one Phase II study in SLE
- AbbVie declined to opt-in for RA and Ablynx is now preparing for regulatory meetings and exploring potential new partnerships

RA: rheumatoid arthritis
SLE: systemic lupus erythematosus

Vobarilizumab

2016 clinical achievements

- Completed Phase IIb monotherapy study in 251 RA patients:
  - vobarilizumab significantly increased the number of patients in clinical remission[1] at week 12 as compared to tocilizumab (41% vs 27%)
- Completed Phase IIb combination study with methotrexate in 345 RA patients:
  - 49% of vobarilizumab-treated patients achieved clinical remission[1] at week 24
- Completed recruitment of 312 patients in Phase II study in patients with SLE

[1]Clinical remission: $DAS28_{CRP} < 2.6$

Vobarilizumab

Key potential milestones



Strategic partnerships

>€400M cash received and >€7Bn in potential milestones plus royalties

Ablynx

Strategic partnerships

2016 achievements and post year-end events

Boehringer Ingelheim

Strategic Alliance signed in September 2007

- >€100 million received to date
- 4 active programmes with focus on difficult targets and bi-specific combinations

- BI initiated a **Phase Ib study with a bi-specific anti-VEGF/Ang2 Nanobody** in patients with solid tumours in January 2016, triggering an €8 million milestone
- BI initiated a **Phase I study with an anti-CX3CR1 (GPCR) Nanobody** as a potential target for chronic kidney disease in April 2016, triggering an €8 million milestone

NOVARTIS

Agreement signed in December 2005, to discover and develop novel Nanobody-based therapeutics against a number of disease targets

- Novartis received clearance for its IND application to begin a **Phase I study with a Nanobody against CXCR2 (GPCR)** in April 2016, triggering an undisclosed milestone

MERCK

Co-discovery and co-development collaboration signed in September 2008

- €10 million in upfront and €4.5 million in milestone payments received to date

- Encouraging **Phase Ib data with anti-IL-17A/F bi-specific Nanobody** in patients with moderate to severe psoriasis, reported in January 2017

Strategic partnerships

2016 achievements and post year-end events

MERCK

Extensive immuno-oncology collaboration signed in 2014 and expanded in 2015

- includes up to 17 programmes with a focus on multi-specific combinations
- €33 million in upfront and €3.5 million in milestone payments received to date
- currently >40 FTEs fully funded at Ablynx
- up to €5.7 billion in potential future milestones plus royalties

- **Excellent progress in 2016, resulting in the first Nanobody expected to enter clinical trials in 2017**

MERCK

Ion channel collaboration signed in 2012 and expanded in 2015 and 2016

- €13.8 million in upfront payments and research funding received to date

- **Second extension agreement** announced in October 2016, triggering a €1 million milestone and extending research funding to 2018

novo nordisk®

Global drug discovery collaboration signed in 2015 with a focus on multi-specific Nanobodies in an undisclosed disease area

- €5 million in upfront received and up to €4 million in research funding during the initial three-year research term

- **Initial discovery milestone achieved** with a multi-specific Nanobody in November 2016, triggering a €1 million payment

Outlook

Potential value enhancing events

Ablynx

2017 outlook

Focus on sustainable value creation

Corporate

- Filing for approval of caplacizumab in Europe ✓
- Further develop commercial organisation in preparation for caplacizumab launch
- End-of-Phase II meetings for vobarilizumab
- Explore partnering opportunities for vobarilizumab in RA

Pipeline

- Continue recruitment in the Phase IIb RSV study with ALX-0171 in 180 hospitalised infants
- Complete Phase II study in ~300 SLE patients with vobarilizumab
- Start clinical development for Japan with both caplacizumab and ALX-0171
- Start pre-clinical and clinical development in new indications for caplacizumab and ALX-0171 respectively
- Start clinical development for at least 2 partnered programmes
- Start Phase III RA study for vobarilizumab (depending on partnering discussions)

Potential study results

- HERCULES Phase III results for caplacizumab in H2
- Phase Ib results for ALX-0761/M1095 (anti-IL17A/F) in psoriasis with Merck KGaA in H1 ✓
- Phase Ib results for anti-VEGF-Ang2 with BI in H2



Questions

CONTACT DETAILS

Investor Relations

+32 9 262 00 00

investors@ablynx.com

www.ablynx.com

Ablynx